Tesamorelin vs CJC-1295: evidence, safety and FDA status
PepsRadar · Comparison · AI-assisted, written from the checked facts on each profile · Content updated (how dates work) · Not reviewed by a medical professional
The short answer
Both mimic growth-hormone-releasing hormone (GHRH). Tesamorelin is FDA-approved for one use: reducing excess abdominal fat in people with HIV-associated lipodystrophy. CJC-1295 is unapproved, and its human trials measured hormone levels only.
Key differences
Tesamorelin has randomized trials: visceral fat fell 15.2% with tesamorelin and rose 5.0% with placebo, and a later trial lowered liver fat.
CJC-1295’s trials found growth hormone rose two- to tenfold and IGF-1 1.5- to threefold after a single exposure. They used the long-acting (DAC) form; most sellers offer a “no DAC” version, which is a different preparation.
Tesamorelin’s label warns of joint pain, swelling, injection-site reactions and higher blood sugar. For CJC-1295, FDA cites a faster heart rate and a body-wide vasodilation reaction.
Tesamorelin clears quickly (its label gives a half-life of about 8 minutes); the DAC form of CJC-1295 kept hormone levels raised for six days or more.
Tesamorelin is a prescription peptide for excess abdominal fat in HIV-associated lipodystrophy. It is not a general weight-loss medicine.
CJC-1295 is a growth-hormone-releasing-hormone analogue. The foundational human trials studied a long-acting preparation and measured endocrine responses.
Human evidence
2 randomized trials
No randomized trials · pharmacology trials · physiology study
Human safety data
FDA label. Tesamorelin is a GHRH analog approved to reduce excess belly fat in people with HIV; it raises IGF-1 and can cause joint pain, swelling, injection-site reactions and higher blood sugar.
Very limited. CJC-1295 is an unapproved growth-hormone-releasing analogue. Small, short trials reported no serious reactions, but FDA cites serious events including a faster heart rate and a body-wide vasodilation reaction.
Boxed warning
None on the FDA label
No FDA label to carry one
Serious risks
Possible growth or return of cancers
Raised IGF-1 levels with unknown long-term effects
Fluid retention, including carpal tunnel syndrome
Glucose intolerance or diabetes
Allergic reactions
Higher death risk if used during acute critical illness
FDA: increased heart rate and systemic vasodilatory reaction reported
FDA: possible immune reactions (immunogenicity) and peptide-impurity problems with compounded products
Partly supported: Peptides like CJC-1295/ipamorelin are a safe, natural way to boost growth hormone.
Each row comes from the Tesamorelin and CJC-1295 profiles, where every fact links to its source. “Conditions flagged” lists the health conditions each profile’s Risks & interactions section mentions.
The human studies
Tesamorelin
HIV-associated abdominal-fat trial (2007)
Human randomized trial · 412 people with HIV and abdominal fat accumulation; 86% were men.
Visceral fat decreased 15.2% with tesamorelin and increased 5.0% with placebo. Some lipid measures also improved. IGF-I increased by 81.0% versus a 5.0% decrease with placebo. More tesamorelin recipients withdrew because of adverse events, despite no significant overall adverse-event difference.
Limitation: Visceral-fat change is not the same as total body-weight loss. The trial population and HIV-associated condition are central; long-term cardiovascular benefit was not established by this endpoint.
Human randomized trial · 61 people with HIV and a hepatic fat fraction of at least 5% were enrolled; the abstract reports 30 receiving tesamorelin and 30 placebo.
The between-group effect on hepatic fat fraction was −4.1 percentage points (95% CI −7.6 to −0.7), corresponding to a 37% relative reduction from baseline. Liver fat fraction fell below 5% in 35% versus 4%. Fasting glucose and HbA1c changes did not differ between groups at 12 months.
Limitation: The population had HIV and fatty liver; generalization beyond this group is unestablished. The primary result concerns liver fat, not proof of fewer cirrhosis complications or longer survival. The abstract calls for longer-term histology studies.
Human pharmacology trials · Healthy adults aged 21–61.
Mean growth hormone rose two- to tenfold for at least six days; IGF-1 rose 1.5- to threefold for nine to eleven days after a single exposure. The estimated half-life was 5.8–8.1 days.
Limitation: The endpoints were hormone concentrations. These were studies of long-acting CJC-1295, not proof of muscle gain or equivalence to products labeled “CJC no DAC.”
Growth-hormone pulsatility after long-acting CJC-1295 (2006)
Human physiology study · Healthy men aged 20–40 years.
GH pulses persisted. Trough GH increased markedly, while mean GH and IGF-I also increased. Pulse frequency and magnitude were not significantly altered in the reported assessment.
Limitation: Short physiological follow-up in healthy men. These results concern the long-acting albumin-binding compound and should not be assigned automatically to products called “CJC without DAC.”
Results from different trials are not a head-to-head comparison: the people, preparations, durations and measures differ.
Bottom line
Research-market tesamorelin is not the approved medicine, and CJC-1295 has no approved use. Neither is approved for muscle building or general fat loss.
PepsRadar does not give doses or usage instructions, and this page is not medical advice. For a prescription medicine, talk to your prescriber or pharmacist.
Plain-English summaries of new peptide studies, regulatory news and notable price changes from the sellers we track. No dosing advice. Unsubscribe anytime.
Peps